Gene transfer targeted to the lung is a promising approach for the treatment of numerous lung diseases, such as cancers or cystic fibrosis. The ideal delivery strategy for such a therapy would be one that allows the gene of interest to specifically target the lung. When using viral vectors, local administration methods are employed, including aerosolisation, 1,2 nasal instillation, 3 and lobar instillation. 4 Alternatively, nonviral vectors are delivered via systemic 5, 6 or local [7] [8] [9] routes. Whatever the route chosen, the problem remains that gene transfer needs to be located specifically in the targeted organ, ie the lung. This can be confirmed by visualizing the biodistribution of the administered material. Some groups have studied the distribution of lipoplexes, usually looking for the lipoplexes in individual tissues by radioactively labeling the complexes. [10] [11] [12] Alternatively, the cell type transfected in a particular organ (usually the lung) is analyzed by immunohistochemical techniques. 13 However, whole body distribution studies looking at the whole mouse using imaging are rare, and are usually performed on excised organs from dead animals. 14 report deals with the strategy we took to follow our lipoplexes by visualization. This technique has been described for an adenovirus lung deposition study 15 and for observing gene induction. 16 However, to the best of our knowledge, the approach has not been used for a kinetic study of lipoplex distribution in living rodents.
With the aim of developing synthetic gene transfection reagents for cystic fibrosis gene therapy, a few years ago our group developed an original family of cationic lipids, called phosphonolipids. These have been shown to be efficient for gene transfer in vitro, as well as in vivo, particularly in gene transfer to mouse lung tissue. 5, 17, 18 Biodistribution studies using the cationic phosphonolipids/ DNA lipoplexes have been carried out after intravenous administration. These studies show that the lipoplexes are rapidly dissociated and the phosphonolipids degraded. 12 The aim of the present study was first, to assess the biodistribution for each administration route, ie intravenous versus endotracheal spray. Second, to validate the protocols and the devices we used to achieve mouse lung-directed gene transfer, and third, to evaluate the interest and the possible applications of this scintigraphic imaging for animal studies.
The biodistribution study was performed by radiolabeling the plasmid DNA with Tc 99m . The lipoplexes formed were intravenously injected in the first instance. As pre-viously described, 6 the lipoplexes accumulate very rapidly in the lung. The lipoplex aggregates in the lungs are progressively degraded, and the plasmid DNA that has not been internalized is eliminated via the urinary tract ( Figure 1a) . It was noted that the whole lung was reached using this route for lipoplex administration. The significance of the recorded signal cannot be determined beyond the 6 h time-point due to some exchange of 99m Tc from the Tc 99m -plasmid chelate with plasma proteins. When administered via an endotracheal spray, the lipoplexes reach only the air volume inside the lungs with the signal much more localized (Figure 1b) . In parallel with a progressive diffusion to the upper lungs, the signal intensity slowly decreases because of an elimination of the radioactivity through the digestive tract due to mucociliary clearance and deglutition.
The relationship between plasmid present in the lungs and expression of the transgene demonstrates that the more plasmid that persists in the lung, the more efficient the transfection. Indeed, the formulation that allows the plasmid DNA to remain in the lungs for the longest times are the ones in which the most luciferase expression is observed, irrespective of the route used for administration (Figures 2a and 3) . The results shown here explain why a formulation that can be efficient when administered via one route is totally inefficient via another. Indeed, formulation A, which exhibits the highest expression when sprayed into the trachea (Figure 3) , is less efficient when injected intravenously (Figure 2 ). This is a consequence of very rapid elimination of the plasmid due to the instability of this formulation in the blood- Gene Therapy stream. In contrast, this formulation allows the greatest persistence of the plasmid in the lung when administered as a spray.
Through these experiments, we have demonstrated the efficiency of our phosphonolipids for gene transfer directed to the lung. Moreover, we have demonstrated the application of the microsprayer as a means to achieve aerosolisation in which the quantity of material that reaches the mouse lung can be accurately determined. This device would facilitate the establishment of a relationship between the aerosolized material and the transfection level obtained. Therefore it would allow the comparison of the efficiency of various nebulized vectors, independently of the nebulization technique used.
With regard to the imaging technique used, firstly, it permits observation of the plasmid biodistribution. This is of particular interest for formulation studies, so that targeting to a specific organ can be improved. Indeed, we have shown that the efficacy of a given preparation depends on the administration route chosen. Secondly, quantification and comparison of the remaining signal intensity allows us to predict the relative efficacy of various preparations. Moreover, imaging the preparation in the animal body allows validation of each administration. Animals with an unsatisfactory distribution can be eliminated from the analysis.
In conclusion, the scintigraphic imaging is of great interest for biodistribution studies, and will allow significant progress to be made in choosing the most valuable lipoplex formulations, particularly when used in combination with reproducible devices, such as the microsprayer.
Figure 2
Correlation between luciferase expression in the lung and plasmid DNA remaining in the lung after intravenous injection. Plasmid DNA was radiolabeled as described in Figure 1 and was combined with the cationic phosphonolipids GLB 43 or GLB 73. Those two lipids were prepared as described in Figure 1 
